A recombinant reporter system for monitoring reactivation of an endogenously DNA hypermethylated gene
Related Experiment Video
Updated: Apr 28, 2026

Pooled shRNA Screen for Reactivation of MeCP2 on the Inactive X Chromosome
Published on: March 2, 2018
Ying Cui1, Frederick Hausheer2, Robert Beaty1
1Authors' Affiliations: Cancer Biology Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;
Abstract:
Reversing abnormal gene silencing in cancer cells due to DNA hypermethylation of promoter CpG islands may offer new cancer prevention or therapeutic approaches. Moreover, such approaches may be broadly applicable to enhance the efficacy of radiotherapy, chemotherapy, or immunotherapy. Here, we demonstrate the powerful utility of a novel gene reporter system to permit studies of the dynamics, mechanisms, and translational relevance of candidate therapies of this type in human colon cancer cells. The reporter system is based on in situ modification of the endogenous locus of the tumor-suppressor gene SFRP1, a pivotal regulator of the Wnt pathway that is silenced by DNA hypermethylation in many colon cancers. The modified SFRP1-GFP reporter allele used remained basally silent, like the unaltered allele, and it was activated only by drug treatments that derepress gene silencing by reversing DNA hypermethylation. We used the established DNA methyltransferase inhibitor (DNMTi) 5-aza-deoxycitidine (DAC) to show how this system can be used to address key questions in the clinical development of epigenetic cancer therapies. First, we defined conditions for which clinically relevant dosing could induce sustained induction of RNA and protein. Second, we found that, in vivo, a more prolonged drug exposure than anticipated was essential to derepress gene silencing in significant cell numbers, and this has implications for generating effective anticancer responses in patients with hematopoietic or solid tumors. Finally, we discovered how histone deacetylase inhibitors (HDACi) alone, when administered to cells actively replicating DNA, can robustly reexpress the silenced gene with no change in promoter methylation status. Taken together, our findings offer a new tool and insights for devising optimal clinical experiments to evaluate DNMTi and HDACi, alone or in combination, and with other cancer treatments, as agents for the epigenetic management and prevention of cancer.
Insights
Researchers developed a novel gene reporter system to study epigenetic cancer therapies. This system helps understand how reversing gene silencing impacts cancer treatment, offering new insights for drug development and patient care.
Area of Science:
- Cancer Biology
- Epigenetics
- Molecular Oncology
Background:
- DNA hypermethylation of CpG islands silences tumor-suppressor genes in cancer.
- Reversing gene silencing presents potential cancer prevention and therapeutic strategies.
- Enhancing radiotherapy, chemotherapy, or immunotherapy efficacy is a key goal.
Purpose of the Study:
- To demonstrate a novel gene reporter system for studying epigenetic therapies in colon cancer cells.
- To investigate the dynamics, mechanisms, and translational relevance of therapies targeting gene silencing.
- To evaluate the utility of the reporter system in understanding epigenetic cancer drug development.
Main Methods:
- Developed a reporter system by modifying the endogenous SFRP1 gene locus with GFP in human colon cancer cells.
- Utilized 5-aza-deoxycitidine (a DNA methyltransferase inhibitor) to test drug-induced gene derepression.
- Assessed RNA and protein induction, drug exposure duration, and the role of histone deacetylase inhibitors (HDACi).
Main Results:
- The SFRP1-GFP reporter system remained silent until activated by drug treatments reversing DNA hypermethylation.
- Clinically relevant dosing of DNA methyltransferase inhibitors (DNMTi) induced sustained RNA and protein expression.
- Prolonged drug exposure was crucial for effective gene silencing reversal in vivo.
- Histone deacetylase inhibitors (HDACi) alone could reexpress silenced genes during active DNA replication without altering methylation status.
Conclusions:
- The novel reporter system provides a powerful tool for studying epigenetic cancer therapies.
- Findings offer insights into optimizing clinical trials for DNMTi and HDACi, alone or in combination.
- This approach aids in the epigenetic management and prevention of cancer.
Related Concept Videos
Reporter Genes
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...

